Cytokinetics, Incorporated (BIT:1CYTK)

Market Cap	6.60B
Revenue (ttm)	73.01M
Net Income (ttm)	-516.27M
Shares Out	n/a
EPS (ttm)	-4.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	11
Open	54.00
Previous Close	54.00
Day's Range	54.00 - 54.00
52-Week Range	26.60 - 54.50
Beta	n/a
RSI	68.78
Earnings Date	Nov 5, 2025

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 498
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CYTK

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial numbers in USD